Nuclear DNA cytophotometry in prostate carcinoma

Area of Science:

• Uro-oncology
• Molecular pathology
• Medical technology

Background:

• Prostate carcinoma presents diagnostic challenges in grading and predicting treatment response.
• DNA content analysis offers a potential method for objective tumor characterization.
• Endocrine therapy is a cornerstone in managing advanced prostate cancer.

Purpose of the Study:

• To investigate the utility of DNA-single-cell fluorescence photometry in assessing prostate carcinoma.
• To correlate DNA histogram patterns with tumor grade and response to endocrine therapy.
• To evaluate the prognostic value of pre- and post-treatment DNA analysis for patient survival.

Main Methods:

• Eighty prostate carcinoma patients underwent fine-needle aspiration biopsy for cytologic grading.
• DNA-single-cell fluorescence photometry was performed before and at 6-month intervals post-endocrine treatment.
• DNA histograms were analyzed for distribution patterns (diploid, hypodiploid, bimodal, scattered) and compared to controls with benign prostatic hypertrophy.

Main Results:

• Pre-therapy DNA histograms showed distinct patterns correlating with tumor grades and differed significantly from benign prostatic hypertrophy.
• Post-therapy, regressive changes included increased diploid/hypodiploid DNA values and loss of secondary peaks.
• Progressive changes like increased scattering and new peaks correlated with clinical remission/stable disease but poorly with progression.
• Survival correlated with pre-therapeutic DNA histograms and specific DNA parameters (median, third-quartile, maximum).

Conclusions:

• DNA-single-cell fluorescence photometry provides valuable insights into prostate carcinoma biology and grade.
• Dynamic changes in DNA histograms during endocrine therapy reflect treatment response.
• Pre-treatment DNA histogram features are significant predictors of patient survival in prostate cancer.